New Agreement

Advanced Medical Solutions Grp PLC
30 April 2004


For immediate release                                            30 April 2004


Advanced Medical Solutions Group plc

Announces distribution deal for use of super-glue for closing surgical wounds in
Orthopaedics

Winsford, UK: Advanced Medical Solutions (AIM: AMS), the global woundcare
technology company, today announces that it has entered into an agreement with
Endo Plus UK Ltd for marketing and distribution of its LiquiBand SurgicalTM
product for orthopaedic use in the UK.

LiquiBand SurgicalTM is a novel medical device that utilises super glue
technology for closing surgical incisions in the operating theatre and provides
benefits over conventional techniques such as suturing and stapling.

This technology has already proven to be very successful for wound closure in
Accident and Emergency (A&E) departments, where AMS' MedLogic division is market
leader in the UK.

The new LiquiBand SurgicalTM product has been designed to meet the requirements
of the surgeon, nursing staff and patient. It consists of a two-part system - a
fast setting, high strength adhesive is used to close the incision and then a
liquid adhesive film is painted over the skin. This sets to provide a
post-operative dressing that is secure, flexible and resistant to water and
bacteria. This form of closure also helps to minimise scarring after surgery
thus providing a good cosmetic result for the patient.

The global market for wound closure is estimated at more than $3 billion, of
which tissue adhesives are a rapidly growing segment. It has been estimated that
up to 40 per cent of wounds currently closed by sutures and staples are suitable
for adhesives. Although these products are becoming routinely used in many A&E
departments, the major market opportunity for them is for closing surgical
incisions in the operating theatre.

The new LiquiBand SurgicalTM product, which was approved for sale throughout
Europe in December 2003, has been introduced into the UK by the MedLogic direct
sales team and is also being rolled out throughout Europe using new and existing
distributors that have a good understanding of the surgical wound closure
market, a presence in the operating theatre and a willingness to focus on new,
innovative products.

The initial response to the product from surgeons has been extremely positive
with successful closures ranging from small keyhole incisions to major wounds.

A particular area of interest is in orthopaedic surgery where the product offers
benefits over sutures and staples for closing incisions after joint replacement.
By partnering with Endo Plus, AMS believes it can achieve strong sales support
for the product in this particular area.

Endo Plus UK, which has a sales team of 10 covering the UK orthopaedic surgeon
community, manufactures and distributes a wide range of hip and knee replacement
products. It is ideally placed to support the introduction of LiquiBand
SurgicalTM for use in orthopaedic surgery.

Commenting on this announcement Dr Don Evans, CEO of AMS, stated:

'Our early experiences with LiquiBand SurgicalTM confirm that this is a very
exciting product that can offer real benefits to surgeons, post-operative
nursing staff and patients compared with conventional methods of wound closure.

'With its strong presence and relationships with orthopaedic surgeons and
theatre staff in the UK I believe that Endo Plus is ideally placed to deliver
success with this product.'

Mr Phil Davies, Managing Director of Endo Plus, added:

'We are always very interested in products that add value to our current range.
Initial clinical evaluations have demonstrated that LiquiBand SurgicalTM is an
excellent product for closure of orthopaedic surgical wounds and we look forward
to expanding its usage in this area throughout the UK.

'There is the potential for this product to revolutionise the way surgical
wounds are closed. Eliminating the need for the removal of sutures or staples is
very good news for both hospitals and patients.'

- ENDS -

For further information, please contact:

Advanced Medical Solutions Group plc           Tel : [phone]

Don Evans, Chief Executive
Mary Tavener, Finance Director
www.admedsol.com
------------------

Buchanan Communications                        Tel: [phone]

Mark Court, Mary-Jane Johnson

Notes to Editors:

Advanced Medical Solutions is a leading company in the development and
manufacture of products for the $15 billion global woundcare market.

Founded in 1991 and currently quoted on AIM, Advanced Medical Solutions is
focused on the design, development and manufacture of innovative and
technologically advanced products for woundcare and other medical applications.

In-house natural and synthetic polymer technology is used to provide advanced
wound dressings based on the moist healing principle. AMS's resources ensure a
unique position as a vertically integrated 'one stop shop' to provide all
categories of moist wound healing products. The Company has the capability to
move from product design and development through to production and delivery
ready for distribution into customer markets.

The acquisition of MedLogic in 2002 has brought AMS products and technology in
cyanoacrylate based tissue adhesives and sealants sold direct to hospitals or
through distributors.

AMS's technology and products currently serve the majority of the key global
markets with strategic partners including 3M, Novartis, Johnson & Johnson,
Molnlycke Healthcare, Coloplast, Smith & Nephew and Beiersdorf.




                      This information is provided by RNS
            The company news service from the London Stock Exchange